Who
Samuel Agresta
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, OnKure Therapeutics; Chief Medical Officer, Foghorn Therapeutics; Chief Medical Officer, Infinity Pharmaceuticals.
In numbers
- Trades disclosed
- 27
- Buys
- 0
- Sells
- 1
- Bought
- $0
- Sold
- $2.6M
- Companies
- 3
- Companies where not an officer
- 0
- First trade
- 6 Aug 2018
- Last trade
- 7 Aug 2026
- Last filed
- 11 Aug 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month. 1 lines have no legible date and are left out.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,588 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,588 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —50,000 at $0.00 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —18,588 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,588 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —131,396 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,396 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code D | —131,396 | filing |
| 7 Aug 2026filed 11 Aug 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,396 | filing |
| 1 Apr 2026filed 3 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 1 Apr 2026filed 3 Apr 2026 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 27 Jan 2025filed 29 Jan 2025 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
| 4 Oct 2024filed 8 Oct 2024 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —18,588 | filing |
| 4 Oct 2024filed 8 Oct 2024 | OKUR OnKure Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —131,396 at $0.00 | filing |
| 16 Aug 2023filed 18 Aug 2023 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code M | —311,297 at $0.00 | filing |
| 16 Aug 2023filed 18 Aug 2023 | FHTX Foghorn TherapeuticsBiotechnology | SEC FORM 4 Code M | $1.2M311,297 at $3.72 | filing |
| 16 Aug 2023filed 18 Aug 2023 | FHTX Foghorn TherapeuticsBiotechnology | SEC FORM 4 Sold | $2.6M311,297 at $8.25 | filing |
| 26 Jan 2023filed 30 Jan 2023 | FHTX Foghorn Therapeuticsoption or derivative · Biotechnology | SEC FORM 4 Code A | —60,000 at $0.00 | filing |
| 16 Jun 2022filed 16 Jun 2022 | Infinity Pharmaceuticalsoption or derivative | SEC FORM 4 Code A | —45,000 at $0.00 | filing |
News
Head-To-Head Analysis: Foghorn Therapeutics (NASDAQ:FHTX) vs. Genelux (NASDAQ:GNLX)FHTX · themarketsdaily.com · 11 Oct 2026
0 headlines in the last 90 days name Samuel Agresta; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.